FOLR1, folate receptor alpha, 2348

N. diseases: 174; N. variants: 8
Disease: Triple Negative Breast Neoplasms ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C3539878
Disease: Triple Negative Breast Neoplasms
Triple Negative Breast Neoplasms 		0.050 GeneticVariation disease BEFREE The correlation between <sup>89</sup>Zr-M9346A tumor uptake and treatment response using IMGN853 in FRα<sup>high</sup> TNBC PDX model suggested the potential of <sup>89</sup>Zr-M9346A PET as a noninvasive tool to prescreen patients based on the in vivo PET imaging for IMGN853-targeted treatment. 31369274 2019
CUI: C3539878
Disease: Triple Negative Breast Neoplasms
Triple Negative Breast Neoplasms 		0.050 AlteredExpression disease BEFREE Moreover, MOv18-IgG1 triggered immune-dependent cancer cell death <i>in vitro</i> by human volunteer and breast cancer patient immune cells, and significantly restricted orthotopic and patient-derived xenograft growth.<b>Conclusions:</b> FRα is overexpressed in high-grade TNBC and postchemotherapy residual tumors. 30068707 2018
CUI: C3539878
Disease: Triple Negative Breast Neoplasms
Triple Negative Breast Neoplasms 		0.050 AlteredExpression disease BEFREE Recently, folate receptor alpha (FRA) is found to be expressed on 80% of TNBC with high expression correlating with poor prognosis. 30155754 2018
CUI: C3539878
Disease: Triple Negative Breast Neoplasms
Triple Negative Breast Neoplasms 		0.050 Biomarker disease BEFREE Immunohistochemistry was performed for FOLR1 in 76 cases of primary TNBC. 28410844 2017
CUI: C3539878
Disease: Triple Negative Breast Neoplasms
Triple Negative Breast Neoplasms 		0.050 AlteredExpression disease BEFREE Taken together, our results show that FRα CAR T cells can mediate antitumor activity against established TNBC tumor, particularly when FRα is expressed at higher levels. 27439908 2016